LIQUIDIA ALERT: Bragar Eagel & Squire, P.C. is Investigating Liquidia Corporation on Behalf of Liquidia Stockholders and Encourages Investors to Contact the Firm

Core Viewpoint - Liquidia Corporation is under investigation for potential violations of federal securities laws and unlawful business practices following a significant stock price drop after FDA news [1][2]. Group 1: Company Developments - On August 19, 2024, Liquidia announced that the FDA granted tentative approval for YUTREPIA™ (treprostinil) inhalation powder to treat adults with pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD) [2]. - The company must wait for the expiration of regulatory exclusivity of a competing product before final approval can be granted [2]. - Following this announcement, Liquidia's stock price fell by $4.32 per share, or 30.62%, closing at $9.79 per share on the same day [2]. Group 2: Legal Investigation - Bragar Eagel & Squire, P.C. is investigating potential claims against Liquidia on behalf of its stockholders [1]. - The investigation focuses on whether Liquidia has violated federal securities laws or engaged in other unlawful business practices [1].